Numerous clinical trials evaluate verteporfin across Phase 1 through Phase 4 studies for ophthalmic, oncologic, and dermatologic indications, including age-related macular degeneration, choroidal neovascularization, recurrent glioblastoma, and surgical scar formation. Sponsored by academic institutions like Emory University, government bodies such as the National Cancer Institute, and pharmaceutical companies including Novartis, these trials encompass active recruiting protocols, upcoming early-phase wound healing studies, completed combination therapy trials, and terminated investigations.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06306638 | RECRUITING | Malignant Solid Neoplasm |
Roswell Park Cancer Institute |
2024-10-01 | PHASE1; PHASE2 |
| NCT06381154 | ACTIVE_NOT_RECRUITING | Locally Advanced Pancreatic Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Adenocarcinoma |
Mayo Clinic |
2024-12-06 | PHASE2 |
| NCT07488988 | NOT_YET_RECRUITING | Surgical Scar |
Odense University Hospital |
2026-06 | PHASE2 |
| NCT06807359 | RECRUITING | Prostate Cancer |
SpectraCure AB |
2025-01-06 | PHASE1; PHASE2 |
| NCT03067051 | RECRUITING | Recurrent Prostate Cancer |
SpectraCure AB |
2017-03-21 | PHASE1; PHASE2 |
| NCT06944249 | NOT_YET_RECRUITING | Scar Formation |
Jöri Pünchera |
2025-05-08 | PHASE1; PHASE2 |
| NCT04590664 | RECRUITING | Glioblastoma; Recurrent Glioblastoma |
Emory University |
2021-01-15 | PHASE1; PHASE2 |
| NCT04075136 | WITHDRAWN | Exudative Age Related Macular Degeneration |
Wake Forest University Health Sciences |
2023-03-30 | PHASE4 |
| NCT03033225 | COMPLETED | Advanced Pancreatic Carcinoma; Locally Advanced Pancreatic Carcinoma; Metastatic Pancreatic Carcinoma; Pancreatic Neoplasm; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Carcinoma |
Mayo Clinic |
2017-05-31 | PHASE2 |
| NCT03906643 | WITHDRAWN | Solid Tumor |
Herbert Lyerly |
2020-07-15 | PHASE1 |
| NCT05390619 | UNKNOWN | Central Serous Chorioretinopathy; Therapy, Photodynamic |
Peking University People's Hospital |
2020-01-01 | |
| NCT04590664 | Recruiting | Glioblastoma|Recurrent Glioblastoma |
Emory University|National Cancer Institute (NCI) |
2021-01-15 | Phase 1|Phase 2 |
| NCT02821520 | COMPLETED | Polypoidal Choroidal Vasculopathy |
The Eye Hospital of Wenzhou Medical University |
2017-01 | PHASE4 |
| NCT02939274 | UNKNOWN | Metastatic Breast Cancer |
Rogers Sciences Inc. |
2016-10 | PHASE2 |
| NCT02702700 | TERMINATED | Pleural Effusion, Malignant |
Centre Hospitalier Universitaire Vaudois |
2016-01 | PHASE1 |
| NCT03797547 | Unknown status | Myopic Choroidal Neovascularisation |
Poitiers University Hospital |
2018-06-22 | -- |
| NCT02457026 | WITHDRAWN | Neovascular Age-related Macular Degeneration |
Duke University |
2016-01 | |
| NCT02872064 | COMPLETED | Breast Neoplasms |
University College, London |
2013-01 | |
| NCT01922102 | COMPLETED | Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM) |
Novartis Pharmaceuticals |
2013-09-11 | PHASE3 |
| NCT01846273 | COMPLETED | Age-related Macular Degeneration; Polypoidal Choroidal Vasculopathy |
Novartis Pharmaceuticals |
2013-08-07 | PHASE4 |
| NCT01746875 | TERMINATED | Macular Degeneration; Retinal Detachment |
Norwegian University of Science and Technology |
2014-02 | |
| NCT03459144 | COMPLETED | Polypoidal Choroidal Vasculopathy |
Sun Yat-sen University |
2012-12-01 | |
| NCT01846273 | Completed | Age-related Macular Degeneration|Polypoidal Choroidal Vasculopathy |
Novartis Pharmaceuticals|Novartis |
2013-08-07 | Phase 4 |
| NCT01968486 | COMPLETED | Myopia, Degenerative |
University of Campania Luigi Vanvitelli |
2012-06 | PHASE1 |
| NCT01256580 | WITHDRAWN | Choroidal Neovascularization; Myopia; Punctate Inner Choroidopathy (PIC); Multifocal Choroiditis; Ocular Histoplasmosis Syndrome; Central Serous Chorioretinopathy (CSC); Angioid Streaks; Trauma, or Hereditary Eye Diseases |
Massachusetts Eye and Ear Infirmary |
2010-08 | |
| NCT01325181 | COMPLETED | Chronic Central Serous Chorioretinopathy |
Jang Won Heo |
2009-07 | PHASE1; PHASE2 |
| NCT01217944 | COMPLETED | Pathological Myopia |
Novartis Pharmaceuticals |
2010-10 | PHASE3 |
| NCT01570608 | COMPLETED | Age Related Macular Degeneration |
The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery |
2007-03 | PHASE3 |
| NCT00570193 | COMPLETED | Choroidal Neovascularization; Macular Degeneration |
Mid-Atlantic Retina Consultations, Inc. |
2006-12 | PHASE1; PHASE2 |
| NCT01360151 | UNKNOWN | Polypoidal Choroidal Vasculopathy |
Seoul St. Mary's Hospital |
2011-02 | |
| NCT00527475 | COMPLETED | Macular Degeneration |
Texas Retina Associates |
2007-05 | PHASE2 |
| NCT01019668 | COMPLETED | Central Serous Chorioretinopathy |
Shin Kong Wu Ho-Su Memorial Hospital |
2008-11 | |
| NCT00546936 | UNKNOWN | Presumed Ocular Histoplasmosis (POHS) |
Barnes Retina Institute |
2007-10 | PHASE2 |
| NCT00436553 | COMPLETED | Macular Degeneration; Choroidal Neovascularization |
Novartis |
2007-02 | PHASE3 |
| NCT00433017 | TERMINATED | Macular Degeneration; Choroidal Neovascularization |
Novartis |
2007-05 | PHASE2; PHASE3 |
| NCT00574093 | COMPLETED | Neovascular Age Related Macular Degeneration |
Fondazione G.B. Bietti, IRCCS |
2008-01 | PHASE2 |
| NCT00473642 | COMPLETED | Age-Related Maculopathy; Choroidal Neovascularization |
Oklahoma State University Center for Health Sciences |
2007-05 | PHASE4 |
| NCT00674323 | COMPLETED | Polypoidal Choroidal Vasculopathy |
Novartis |
2008-04 | PHASE4 |
| NCT00492284 | COMPLETED | Choroidal Neovascularization; Macular Degeneration |
QLT Inc. |
2007-07 | PHASE2 |
| NCT00331435 | COMPLETED | Age Related Macular Degeneration |
Ophthalmic PDT Study Group |
2006-06 | PHASE4 |
| NCT00390208 | COMPLETED | Age Related Macular Degeneration |
Bay Area Retina Associates |
2006-08 | PHASE2 |
| NCT00390026 | WITHDRAWN | Age-related Macular Degeneration |
St. Erik Eye Hospital |
2006-11 | PHASE3 |
| NCT00729846 | COMPLETED | Age Related Macular Degeneration; Choroidal Neovascularization; Macular Edema |
California Retina Consultants |
2006-05 | PHASE2 |
| NCT00359164 | COMPLETED | Macular Degeneration |
University of British Columbia |
2006-07 | PHASE2 |
| NCT01032109 | COMPLETED | Age-related Macular Degeneration |
Kumamoto University |
2006-10 | |
| NCT00967213 | COMPLETED | Neovascular Age-related Macular Degeneration |
Novartis Korea Ltd. |
2006-08 | PHASE3 |
| NCT00696592 | WITHDRAWN | Neovascular Age-related Macular Degeneration |
University of Padova |
2007-01-31 | PHASE2 |
| NCT00242580 | COMPLETED | Macular Degeneration; Choroidal Neovascularization |
Novartis Pharmaceuticals |
2005-09 | PHASE3 |
| NCT00094120 | TERMINATED | Macular Degeneration |
Genaera Corporation |
2004-10 | PHASE2 |
| NCT00423189 | Terminated | Age-Related Macular Degeneration |
David M. Brown M.D.|Novartis Pharmaceuticals|Greater Houston Retina Research |
2007-01 | Phase 4 |
| NCT00403442 | Terminated | Macular Degeneration |
Vitreous -Retina- Macula Consultants of New York|QLT Inc. |
2006-09 | Phase 1 |
| NCT00347399 | TERMINATED | Age Related Macular Degeneration |
Asociación para Evitar la Ceguera en México |
2006-03 | PHASE2 |
| NCT00930189 | WITHDRAWN | Subfoveal Choroidal Neovascularization |
Asociación para Evitar la Ceguera en México |
2006-04 | PHASE2; PHASE3 |
| NCT00049959 | TERMINATED | Basal Cell Carcinoma; Nevoid Basal Cell Carcinoma Syndrome; Gorlin Syndrome |
QLT Inc. |
PHASE3 | |
| NCT00148551 | UNKNOWN | Age-Related Macular Degeneration |
Canadian Retinal Trials Group |
2004-01 | PHASE2; PHASE3 |
| NCT00134667 | TERMINATED | Age-Related Macular Degeneration |
Eyetech Pharmaceuticals |
2005-03 | PHASE4 |
| NCT00211445 | COMPLETED | Chronic Central Serous Chorioretinopathy |
Manhattan Eye, Ear & Throat Hospital |
2002-07 | PHASE2 |
| NCT00288561 | COMPLETED | Age-Related Macular Degeneration (ARMD) |
Novartis |
2004-11 | PHASE2 |
| NCT00061594 | COMPLETED | Macular Degeneration |
Genentech, Inc. |
2003-05 | PHASE3 |
| NCT00007969 | COMPLETED | Melanoma (Skin) |
QLT Inc. |
2000-10 | PHASE1; PHASE2 |
| NCT00370539 | UNKNOWN | Neovascular Age-Related Macular Degeneration |
Shahid Beheshti University of Medical Sciences |
2006-09 | PHASE3 |
| NCT00002647 | UNKNOWN | Brain and Central Nervous System Tumors; Metastatic Cancer |
Medical College of Wisconsin |
1994-05 | PHASE1 |
| NCT00135837 | COMPLETED | Age-Related Macular Degeneration |
Novartis |
2003-06 | PHASE4 |
| NCT00211419 | COMPLETED | Maculopathy, Age-Related |
Manhattan Eye, Ear & Throat Hospital |
PHASE1 | |
| NCT00403442 | TERMINATED | Macular Degeneration |
Vitreous -Retina- Macula Consultants of New York |
2006-09 | PHASE1 |
| NCT00471406 | COMPLETED | Corneal Neovascularization |
Chonnam National University Hospital |
||
| NCT00426998 | COMPLETED | Choroidal Neovascularization; Macular Degeneration |
Retinal Consultants Medical Group |
2006-04 | PHASE2 |
| NCT00056823 | COMPLETED | Age-Related Maculopathy |
Genentech, Inc. |
2003-03 | PHASE1; PHASE2 |
(data from https://clinicaltrials.gov, updated on 2026-04-06)
Check the
Verteporfin
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- Verteporfin Mechanism of Action: YAP Inhibition in Fibroblast Research
- Verteporfin: Selectivity & Specificity
- Verteporfin Working Concentration | Cell Culture | Treatment
- Verteporfin Solubility in DMSO
- Verteporfin Storage
- Verteporfin Stability
- Verteporfin Combination Database
- Verteporfin Molecular Weight
- Verteporfin SMILES
- Verteporfin CAS Number
- Verteporfin Chemical Structure (2D and 3D)
- Verteporfin IC50 for Cell-based and Cell-free Assays
- Verteporfin Sigma (SML0534)? Try a better option.
- Verteporfin Cell Signaling Technology (64260)? Try a better option.
- Verteporfin MedChemExpress (HY-B0146)? Try a better option.
- Verteporfin Cayman (17334)? Try a better option.
- Verteporfin STEMCELL (100-0262)? Try a better option.
- Verteporfin SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.